KEVIN GAREY to Treatment Outcome
This is a "connection" page, showing publications KEVIN GAREY has written about Treatment Outcome.
Connection Strength
0.535
-
Age-Stratified Treatment Response Rates in Hospitalized Patients with Clostridium difficile Infection Treated with Metronidazole. Antimicrob Agents Chemother. 2015 Oct; 59(10):6113-6.
Score: 0.042
-
FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014 Sep 15; 59(6):819-25.
Score: 0.038
-
Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy. J Hosp Infect. 2013 Sep; 85(1):28-32.
Score: 0.036
-
Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother. 2013 Feb; 68(2):438-43.
Score: 0.034
-
Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother. 2012 Jun; 56(6):3239-43.
Score: 0.033
-
A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011 Dec; 66(12):2850-5.
Score: 0.032
-
Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy. J Med Assoc Thai. 2011 Jul; 94(7):863-70.
Score: 0.031
-
High Horn's index score predicts poor outcomes in patients with Clostridium difficile infection. J Hosp Infect. 2011 Sep; 79(1):23-6.
Score: 0.031
-
Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother. 2010 Sep; 54(9):3717-22.
Score: 0.029
-
Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther. 2010 May; 8(5):555-64.
Score: 0.029
-
Crofelemer, a novel agent for treatment of secretory diarrhea. Ann Pharmacother. 2010 May; 44(5):878-84.
Score: 0.029
-
Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2009 Mar; 63(3):279-85.
Score: 0.026
-
Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008 Mar 15; 46(6):862-7.
Score: 0.025
-
High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. Curr Med Res Opin. 2007 May; 23(5):1057-65.
Score: 0.023
-
Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study. Int J Antimicrob Agents. 2007 May; 29(5):557-62.
Score: 0.023
-
Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response. Clin Infect Dis. 2024 07 19; 79(1):15-21.
Score: 0.019
-
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response. Clin Infect Dis. 2024 06 14; 78(6):1462-1472.
Score: 0.019
-
Cadazolid for the treatment of Clostridium difficile. Expert Opin Investig Drugs. 2017 Apr; 26(4):509-514.
Score: 0.012
-
Improving patient care through implementation of an antimicrobial stewardship program. Am J Health Syst Pharm. 2011 Nov 15; 68(22):2170-4.
Score: 0.008
-
Future novel therapeutic agents for Clostridium difficile infection. Expert Opin Investig Drugs. 2010 Jul; 19(7):825-36.
Score: 0.007
-
Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital. Pharm World Sci. 2009 Oct; 31(5):565.
Score: 0.007